(ZYME) Zymeworks Common Stock - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.789m USD | Total Return: 123.1% in 12m
Avg Turnover: 15.3M
Qual. Beats: -1
Rev. Trend: -38.8%
Qual. Beats: -2
Warnings
Interest Coverage Ratio -52.0 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -2.36 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Zymeworks Inc. (ZYME) is a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for oncology and inflammatory diseases. The company utilizes four core technology platforms-Azymetric, EFECT, ProTECT, and its proprietary Antibody-Drug Conjugate (ADC) suite-to engineer antibodies with enhanced targeting and effector functions. Its lead candidate, zanidatamab (Ziihera), is a bispecific antibody targeting HER2-expressing tumors, supported by a pipeline of ADCs and T-cell engagers addressing various solid tumors and prostate cancer.
The company operates under a platform-based business model, leveraging its intellectual property to secure high-value strategic partnerships with major pharmaceutical entities including Bristol-Myers Squibb, Jazz Pharmaceuticals, and Janssen. In the biotechnology sector, this model allows smaller firms to offset high R&D costs through milestone payments and royalties while retaining rights to core assets. ADCs represent a significant growth area in the sector, as they combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs to minimize off-target toxicity.
For a deeper dive into these partnership structures and pipeline valuations, ValueRay provides additional data points to support your due diligence. Zymeworks maintains its corporate headquarters in Delaware and continues to expand its clinical portfolio through both internal development and collaborative research agreements.
- FDA approval and commercial launch of Ziihera drive near-term revenue growth
- Milestone payments from Jazz Pharmaceuticals and BMS strengthen cash position
- Clinical trial data for next-generation ADC pipeline influences long-term valuation
- Expansion of Azymetric platform licensing agreements increases high-margin royalty potential
- High R&D expenditure for multi-asset clinical development impacts net loss margins
| Net Income: -102.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA 12.09 > 1.0 |
| NWC/Revenue: 431k% < 20% (prev 258.5%; Δ 430k% < -1%) |
| CFO/TA -0.10 > 3% & CFO -45.7b > Net Income -102.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.7m) vs 12m ago -0.71% < -2% |
| Gross Margin: 86.72% > 18% (prev 0.88%; Δ 8.58k% > 0.5%) |
| Asset Turnover: 0.03% > 50% (prev 21.95%; Δ -21.91% > 0%) |
| Interest Coverage Ratio: -52.03 > 6 (EBITDA TTM -96.4m / Interest Expense TTM 2.07m) |
| A: 0.73 (Total Current Assets 386b - Total Current Liabilities 35.6b) / Total Assets 478b |
| B: -2.25 (Retained Earnings -1074b / Total Assets 478b) |
| C: -0.00 (EBIT TTM -107.5m / Avg Total Assets 239b) |
| D: 0.15 (Book Value of Equity 48.2b / Total Liabilities 315b) |
| Altman-Z'' = -2.36 = D |
| DSRI: 218.4 (Receivables 4.67b/24.6m, Revenue 81.3m/93.4m) |
| GMI: 1.01 (GM 86.72% / 88.01%) |
| AQI: 0.66 (AQ_t 0.13 / AQ_t-1 0.20) |
| SGI: 0.87 (Revenue 81.3m / 93.4m) |
| TATA: 0.10 (NI -102.7m - CFO -45.7b) / TA 478b) |
| Beneish M = 175.7 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 25.11 with a total of 610,194 shares traded.
Over the past week, the price has changed by +7.02%,
over one month by -10.23%,
over three months by +11.40% and
over the past year by +123.08%.
Zymeworks Common Stock has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ZYME.
- StrongBuy: 7
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 40.2 | 59.9% |
P/S = 22.0143
P/B = 10.9851
Revenue TTM = 81.3m USD
EBIT TTM = -107.5m USD
EBITDA TTM = -96.4m USD
Long Term Debt = 13.8b USD (estimated: total debt 17.0b - short term 3.28b)
Short Term Debt = 3.28b USD (from shortTermDebt, last quarter)
Debt = 17.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 18.3m
Net Debt = -164b USD (calculated: Debt 17.1b - CCE 181b)
Enterprise Value = 1.79b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = -52.03 (Ebit TTM -107.5m / Interest Expense TTM 2.07m)
EV/FCF = -0.05x (Enterprise Value 1.79b / FCF TTM -36.1b)
FCF Yield = -2.02k% (FCF TTM -36.1b / Enterprise Value 1.79b)
FCF Margin = -44.5k% (FCF TTM -36.1b / Revenue TTM 81.3m)
Net Margin = -126.3% (Net Income TTM -102.7m / Revenue TTM 81.3m)
Gross Margin = 86.72% ((Revenue TTM 81.3m - Cost of Revenue TTM 10.8m) / Revenue TTM)
Gross Margin QoQ = -18.23% (prev 32.76%)
Tobins Q-Ratio = 0.00 (Enterprise Value 1.79b / Total Assets 478b)
Interest Expense / Debt = 0.01% (Interest Expense 2.07m / Debt 17.1b)
Taxrate = 21.0% (US default 21%)
NOPAT = -84.9m (EBIT -107.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.81 (Total Current Assets 386b / Total Current Liabilities 35.7b)
Debt / Equity = 0.10 (Debt 17.1b / totalStockholderEquity, last quarter 164b)
Debt / EBITDA = 1.70k (out of range, set to none) (Net Debt -164b / EBITDA -96.4m)
Debt / FCF = 4.53 (negative FCF - burning cash) (Net Debt -164b / FCF TTM -36.1b)
Total Stockholder Equity = 41.1b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.04% (Net Income -102.7m / Total Assets 478b)
RoE = -0.01% (Net Income TTM -102.7m / Total Stockholder Equity 1115b)
RoCE = -0.01% (EBIT -107.5m / Capital Employed (Equity 1115b + L.T.Debt 13.8b))
RoIC = -0.02% (negative operating profit) (NOPAT -84.9m / Invested Capital 446b)
WACC = 0.91% (E(1.79b)/V(18.8b) * Re(9.45%) + D(17.1b)/V(18.8b) * Rd(0.01%) * (1-Tc(0.21)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -24.44 | Cagr: 2.39%
[DCF] Fair Price = unknown (Cash Flow -36.1b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.68 | # QB: -1
Revenue Correlation: -38.77 | Revenue CAGR: -26.66% | SUE: -2.27 | # QB: -2
EPS current Quarter (2026-06-30): EPS=-0.39 | Chg30d=-107.79% | Revisions=-50% | Analysts=8
EPS next Quarter (2026-09-30): EPS=1.93 | Chg30d=+4408.16% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=1.38 | Chg30d=+12.13% | Revisions=+11% | GrowthEPS=+227.3% | GrowthRev=+192.2%
EPS next Year (2027-12-31): EPS=0.52 | Chg30d=-34.50% | Revisions=+25% | GrowthEPS=-62.5% | GrowthRev=-29.5%
[Analyst] Revisions Ratio: -50%